InMed Pharmaceuticals Inc. SEC filings INM
InMed Pharmaceuticals Inc. has 514 filings in SEC EDGAR's recent list, going back to Jan 17, 2018. Its latest annual report, Form 10-K, was filed on Sep 9, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Oct 28, 2026 | — |
| 424B3 | Prospectus | Oct 1, 2026 | — |
| S-4/A | Filing | Sep 29, 2026 | — |
| S-4/A | Filing | Sep 9, 2026 | — |
| S-4 | Registration for a merger or exchange | Jul 2, 2026 | — |
| 424B5 | Prospectus supplement | Apr 3, 2026 | — |
| S-3 | Shelf registration | Mar 20, 2026 | — |
| S-8 | Employee stock plan registration | Dec 8, 2025 | — |
| 424B3 | Prospectus | Aug 5, 2025 | — |
| S-1/A | Amended registration statement | Aug 1, 2025 | — |
| S-1 | Registration statement | Jul 9, 2025 | — |
| 424B3 | Prospectus | Jan 2, 2025 | — |
| S-1/A | Amended registration statement | Dec 30, 2024 | — |
| S-1 | Registration statement | Dec 23, 2024 | — |
| S-8 | Employee stock plan registration | Dec 20, 2024 | — |
| 424B3 | Prospectus | Oct 17, 2024 | — |
| 424B3 | Prospectus | Jun 28, 2024 | — |
| S-8 | Employee stock plan registration | Dec 22, 2023 | — |
| 424B3 | Prospectus | Nov 13, 2023 | — |
| S-1 | Registration statement | Nov 8, 2023 | — |
| 424B3 | Prospectus | Dec 15, 2022 | — |
| S-1 | Registration statement | Dec 7, 2022 | — |
| S-8 | Employee stock plan registration | Nov 14, 2022 | — |
| 424B3 | Prospectus | Oct 19, 2022 | — |
| S-1 | Registration statement | Oct 12, 2022 | — |
| S-8 POS | Post-effective amendment no. 1 to form s-8 | Sep 20, 2022 | — |
| S-8 POS | Post-effective amendment no. 1 to form s-8 | Sep 20, 2022 | — |
| POS AM | Post-effective amendment no. 1 to form s-3 | Sep 20, 2022 | — |
| POS AM | Post-effective amendment no. 1 to form s-3 | Sep 20, 2022 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Sep 20, 2022 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Sep 20, 2022 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | Sep 20, 2022 | — |
| 424B3 | Prospectus | Jul 6, 2022 | — |
| S-1/A | Amended registration statement | Jun 24, 2022 | — |
| S-1 | Registration statement | Jun 21, 2022 | — |
| 424B5 | Prospectus supplement | Jun 6, 2022 | — |
| 424B5 | Prospectus supplement | Jun 1, 2022 | — |
| 424B3 | Prospectus | Apr 25, 2022 | — |
| 424B3 | Prospectus | Apr 7, 2022 | — |
| S-3 | Shelf registration | Apr 7, 2022 | — |
| S-3/A | Amendment no. 1 to form s-3 | Feb 9, 2022 | — |
| S-3 | Shelf registration | Feb 4, 2022 | — |
| S-3 | Shelf registration | Feb 4, 2022 | — |
| S-8 | Employee stock plan registration | Oct 18, 2021 | — |
| 424B3 | Prospectus | Jul 22, 2021 | — |
| S-1 | Registration statement | Jul 13, 2021 | — |
| 424B3 | Prospectus | Mar 16, 2021 | — |
| S-1 | Registration statement | Mar 5, 2021 | — |
| S-8 | Employee stock plan registration | Mar 5, 2021 | — |
| 424B4 | Prospectus | Nov 16, 2020 | — |
| S-1/A | Amended registration statement | Oct 15, 2020 | — |
| S-1/A | Amended registration statement | Oct 8, 2020 | — |
| S-1/A | Amended registration statement | Sep 15, 2020 | — |
| S-1/A | Amended registration statement | Jul 21, 2020 | — |
| S-1/A | Amended registration statement | Jul 6, 2020 | — |
| S-1 | Registration statement | Jun 19, 2020 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INM (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1728328
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.